Elutia Inc. Stock Price, News & Analysis

Elutia (NASDAQ: ELUT) has launched a real-world clinical study for EluPro™, their FDA-cleared antibiotic-eluting bioenvelope designed for cardiac implantable electronic devices (CIEDs) and neurostimulators. The first patient enrollment occurred at UC San Diego Health.

The prospective, post-market study aims to evaluate EluPro's performance in standard clinical practice across diverse CIED implantation patients. The study will track 100 patients for 12 months, monitoring complications like infection, hematoma, lead dislodgement, and device migration.

EluPro combines rifampin and minocycline antibiotics with a regenerative biomatrix, addressing the U.S. market where over 600,000 CIEDs are implanted annually with 5-7% complication rates. The CIED protection market is valued at $600 million in the U.S.

Elutia (Nasdaq: ELUT) has announced that global tariffs have not materially impacted its operations or commercial performance. The company's business model, centered on 100% U.S.-based sourcing, manufacturing, and distribution, primarily through its Roswell, Georgia facility, has effectively insulated it from international trade uncertainties.

The company's product portfolio, including EluPro™, CanGaroo®, SimpliDerm®, and its Cardiovascular line, is entirely produced and sold within the United States. The FDA-registered Roswell facility has maintained normal operations without experiencing tariff-related delays, cost increases, or supplier issues. Elutia reports that its pricing and margins remain unaffected by the current global tariff environment.

Elutia (Nasdaq: ELUT) has received a 2025 Bronze Edison Award for their groundbreaking product EluPro™, the first FDA-cleared antibiotic-eluting bioenvelope. The innovation was recognized in the Post-Surgical Recovery Solutions category.

Launched in January 2025, EluPro combines a regenerative biomatrix with rifampin and minocycline antibiotics, designed to protect patients with cardiac implanted electronic devices (CIEDs) and neurostimulation devices. The technology addresses critical needs in the medical device industry, where approximately 600,000 CIEDs are implanted annually in the U.S., with complications occurring in 5-7% of cases.

The award selection process involved rigorous evaluation by the Edison Awards Steering Committee and independent experts, considering concept, value, delivery, and impact. The award ceremony took place on April 3, 2025, at the Luminary Hotel and Caloosa Sound Convention Center in Fort Myers, Florida.

Elutia (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix technologies, has announced its participation in two upcoming investor conferences in April 2025.

The company's leadership team, including Dr. Randy Mills (President and CEO) and Matt Ferguson (CFO), will attend:

• The LD Micro 15th Annual Invitational in New York on April 10, 2025, presenting at 12:30 p.m. ET
• The Planet Microcap Showcase in Las Vegas on April 23, 2025, presenting at 4:00 p.m. ET

Both events will feature company presentations and one-on-one meetings with investors. Institutional investors can schedule meetings through conference representatives or by contacting IR@elutia.com.

Elutia (Nasdaq: ELUT) has announced the upcoming debut of EluPro™, its new Antibiotic-Eluting BioEnvelope, at the Heart Rhythm Society's annual meeting (HRS 2025) in San Diego from April 25-27, 2025. The product is designed for cardiac implantable electronic devices (CIEDs) and neurostimulators.

EluPro features a proprietary biomatrix that naturally conforms around CIEDs, offering a softer alternative to synthetic options. The product combines a dual-antibiotic combination with a natural biomatrix that supports healing while reducing bacterial colonization. Dr. Kimberly Mulligan, GM and VP of Elutia's Cardiovascular Division, emphasized the product's innovative approach to CIED antibiotic envelope technology.

The company will showcase EluPro at booth #2418 at the San Diego Convention Center, offering hands-on experience with the product. Healthcare professionals can schedule meetings through the HRS 2025 meeting portal or contact ir@elutia.com.

Elutia (NASDAQ: ELUT) has announced a new GPO agreement with Advantus Health Partners, marking its seventh GPO agreement since launching EluPro™. The agreement will expand access to EluPro™, the world's first FDA-cleared antibiotic-eluting biologic envelope for cardiac implantable electronic devices and neurostimulators.

EluPro™ combines antibiotics with a natural extracellular matrix that regenerates into patient tissue, addressing post-surgical challenges including infection, migration, and skin erosion. Dr. Kimberly Mulligan, GM and VP of Elutia's Cardiovascular Division, noted that the pilot launch has exceeded expectations, with physicians recognizing the product's unique value in preventing infections.

The partnership with Advantus Health Partners, a healthcare solutions company specializing in supply chain management and cost-savings efficiencies, will help make EluPro™ more widely available to physicians nationwide through their sustainable contracting solutions.

Elutia (Nasdaq: ELUT) has published new preclinical data in Antibiotics journal, demonstrating the effectiveness of its antibiotic-eluting biologic envelope for cardiac implanted electronic devices (CIEDs). The study shows:

The envelope demonstrated complete bacterial eradication across seven different Gram positive and negative organisms, including Staphylococcus aureus, MRSA, and Staphylococcus epidermidis. The technology features rapid initial antibiotic elution followed by gradual release over 14 days.

This research complements the 2024 Garrigos study, validating antimicrobial performance in vivo. The company's product, EluPro, is the first FDA-cleared antibiotic-eluting bioenvelope for CIEDs and neurostimulators, launched commercially in January 2025.

Elutia (NASDAQ: ELUT) reported mixed financial results for Q4 and full year 2024. BioEnvelope product sales showed strong growth, up 18% in Q4 to $2.7M, with same-center sales increasing 65% following EluPro commercialization. The company's newly launched EluPro accounted for over 30% of BioEnvelope sales in Q4.

For full year 2024, BioEnvelope sales rose 5% to $9.9M, while SimpliDerm sales increased 12% to $11.6M. However, overall net sales decreased 1.5% to $24.4M due to declining cardiovascular product sales. The company reported a net loss of $54.1M for 2024, compared to $41.2M in 2023.

EluPro's market penetration has been notable, with 67 approved accounts by year-end and approximately 100 actively ordering accounts. The company strengthened its financial position with a $15M registered direct offering in February 2025.

Elutia (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix technologies, has scheduled the release of its fourth quarter and full year 2024 financial results for Thursday, March 6, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. Management will be available for discussion during the call, which can be accessed through U.S. (877-407-8029) and International (201-689-8029) dial-in numbers using Conference ID 13751810. A live and archived webcast will be available on the company's investor relations website.